{"Boehringer Ingelheim":{"tweets.background":"#F6F6F6","Synonym":"Boehringer Ingelheim GmbH","count":"5","Related disease":["Respiratory disease","Cardiovascular disease","Parkinson's disease","HIV","Thromboembolic disease","Cerebrovascular disease","Cancer","Diabetes","Hepatitis"],"CurationStatus":"curated","tweets.links":"#013C41","tweets.color":"#605C4F","RelatedTo":"Resource:EFPIA","shell.background":"#013C41","Address":["Boehringer Ingelheim GmbH","Corporate Division Communications","Binger Strasse 173","55216 Ingelheim am Rhein"],"SuperCategory":"Commercial Organization","Id":"nlx_158086","Species":["Human"],"user":"{{#show: {{FULLPAGENAME ","DefiningCitation":"http:\/\/www.boehringer-ingelheim.com\/","Keywords":["Drug","Pharmaceutical","Oncology","Medicine"],"Definition":"Private pharmaceutical company headquartered in Ingelheim that operates globally with 140 affiliates and more than 46,000 employees. The company's key assets of interest are: respiratory disease, cardiovascular disease, Parkinson's disease, HIV, thromboembolic disease, cerebrovascular disease, oncology, diabetes and hepatitis. The family-owned company has been committed to researching, developing, manufacturing and marketing products of high therapeutic value for human and veterinary medicine. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. (Adapted from Wikipedia)"}}